CD8A and neoplasm: In contrast, after ADT-tILC2 treatment, animals exhibited a significant increase in infiltrating CD8+, CD4+ T lymphocytes and eosinophils (Figures 5D, E, G, H, J, K), specifying a robust and targeted immune response against the tumor cells.